Role of itraconazole metabolites in CYP3A4 inhibition

Drug Metabolism and Disposition

Volumn 32, Issue 10, 2004, Pages 1121-1131

  Isoherranen, Nina ^a   Kunze, Kent L ^a   Allen, Kyle E ^a   Nelson, Wendel L ^a   Thummel, Kenneth E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; ITRACONAZOLE; KETOCONAZOLE; MIDAZOLAM;

ANTIFUNGAL ACTIVITY; ARTICLE; BIOAVAILABILITY; COMPETITIVE INHIBITION; DRUG CLEARANCE; DRUG DETERMINATION; DRUG EFFECT; DRUG INHIBITION; DRUG POTENCY; ENZYME SUBSTRATE; METABOLITE; NONHUMAN; PRIORITY JOURNAL; STEADY STATE; TISSUE DISTRIBUTION;

CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMANS; ITRACONAZOLE; MICROSOMES, LIVER;

STAPHYLOCOCCUS PHAGE 3A;

EID: 4644321613     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.104.000315     Document Type: Article

References (38)

1. Back DJ and Tjia JF (1991) Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. Br J Clin Pharmacol 32:624-626.
2. Backman JT, Kivisto KT, Olkkola KT, and Neuvonen PJ (1998) The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol 54:53-58.
3. Banerjee R, Leaver N, Lyster H, and Banner NR (2001) Coadministration of itraconazole and tacrolimus after thoracic organ transplantation. Transplant Proc 33:1600-1602.
4. Barone JA, Koh JG, Bierman RH, Colaizzi JL, Swanson KA, Gaffar MC, Moskovitz BL, Mechlinski W, and Van de Velde V (1993) Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. Antimicrob Agents Chemother 37:778-784.
5. Bonay M, Jonville-Bera AP, Diot P, Lemarie E, Lavandier M, and Autret E (1993) Possible interaction between phenobarbital, carbamazepine and itraconazole. Drug Safely 9:309-311.
6. Breadmore MC and Thormann W (2003) Capillary electrophoresis evidence for the stereoselective metabolism of itraconazole in man. Electrophoresis 24:2588-2597.
7. Cervelli MJ and Russ GR (2003) Itraconazole-tacrolimus drug interaction. Ther Drug Monit 25:483-484.
8. Ducharme MP, Slaughter RL, Warbasse LH, Chandrasekar PH, Van de Velde V, Mannens G, and Edwards DJ (1995) Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin. Clin Pharmacol Ther 58:617-624.
9. Florea NR, Capitano B, Nightingale CH, Hull D, Leitz GJ, and Nicolau DP (2003) Beneficial pharmacokinetic interaction between cyclosporine and itraconazole in renal transplant recipients. Transplant Proc 35:2873-2877.
10. Hardin TC, Graybill JR, Fetchick R, Woestenborghs R, Rinaldi MG, and Kuhn JG (1988) Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother 32:1310-1313.
11. Haria M, Bryson HM, and Goa KL (1996) Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. Drugs 51:585-620.
12. Heeres J, Backx LJ, and Van Cutsem J (1984) Antimycotic azoles. 7. Synthesis and antifungal properties of a series of novel triazol-3-ones. J Med Chem 27:894-900.
13. Heykants J, Michielis M, Meuldermans W, Monbaliu J, Lavrijsen K, Van Peer A, Levron JC, Woestenborghs R, and Cauwenbergh G (1987) The pharmacokinetics of itraconazole in animals and man: an overview, in Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents (Fromtling RA ed), pp 223-249, J.R. Prous Science Publishers, Barcelona.
14. Heykants J, Van Peer A, Van de Velde V, Van Rooy P, Meuldermans W, Lavrijsen K, Woestenborghs R, Van Cutsem J, and Cauwenbergh G (1989) The clinical pharmacokinetics of itraconazole: an overview. Mycoses 32 (Suppl 1):67-87.
15. Ishigam M, Uchiyama M, Kondo T, Iwabuchi H, Inoue S, Takasaki W, Ikeda T, Komai T, Ito K, and Sugiyama Y (2001) Inhibition of in vitro metabolism of simvastatin by itraconazole in humans and prediction of in vivo drug-drug interactions. Pharm Res (NY) 18:622-631.
16. Kivistö KT, Lamberg TS, and Neuvonen PJ (1999) Interactions of buspirone with itraconazole and rifampicin: effects on the pharmacokinetics of the active 1-(2-pyrimidinyl)-piperazine metabolite of buspirone. Pharmacol Toxicol 84:94-97.
17. Kwan JT, Foxall PJ, Davidson DG, Bending MR, and Eisinger AJ (1987) Interaction of cyclosporin and itraconazole. Lancet 2:282.
18. Lebrun-Vignes B, Archer VC, Diquet B, Levron JC, Chosidow O, Puech AJ, and Warot D (2001) Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. Br J Clin Pharmacol 51:443-450.
19. Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, Lamba J, Schuetz EG, and Thummel KE (2002) Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 62:162-172.
20. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
21. Mahnke CB, Sutton RM, Venkataramanan R, Michaels M, Kurland G, Boyle GJ, Law YM, Miller SA, Pigula FA, Gandhi S, and Webber SA (2003) Tacrolimus dosage requirements after initiation of azole antifungal therapy in pediatric thoracic organ transplantation. Pediatr Transplant 7:474-478.
22. Neuvonen PJ and Jalava KM (1996) Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 60:54-61.
23. Neuvonen PJ, Kantola T, and Kivisto KT (1998) Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 63:332-341.
24. Obach RS and Reed-Hagen AE (2002) Measurement of Michaelis constants for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach. Drug Metab Dispos 30:831-837.
25. Oda Y and Kharasch ED (2001) Metabolism of levo-alpha-acetylmethadol (LAAM) by human liver cytochrome P450: involvement of CYP3A4 characterized by atypical kinetics with two binding sites. J Pharmacol Exp Ther 297:410-422.
26. Olkkola KT, Ahonen J, and Neuvonen PJ (1996) The effect of systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg 82:511-516.
27. Poirier JM and Cheymol G (1998) Optimisation of itraconazole therapy using target drug concentrations. Clin Pharmacokinet 35:461-473.
28. Schäfer-Körting M (1993) Pharmacokinetic optimisation of oral antifungal therapy. Clin Pharmacokinet 25:329-341.
29. Sugiyama K, Nagata K, Gillette JR, and Darbyshire JF (1994) Theoretical kinetics of sequential metabolism in vitro. Study of the formation of 16 alpha-hydroxyandrostenedione from testosterone by purified rat P450 2C11. Drug Metab Dispos 22:584-591.
30. Tidwell TT (1990) Oxidation of alcohols to carbonyl compounds via alkoxysulfonium ylides: the Moffat, Swern and related oxidations. Org React 39:297-572.
31. Tran TH, Von Moltke LL, Venkatakrishnan K, Granda BW, Gibbs MA, Obach RS, Harmatz JS, and Greenblatt DJ (2002) Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitors. Drug Metab Dispos 30:1441-1445.
32. Trenk D, Brett W, Jahnchen E, and Birnbaum D (1987) Time course of cyclosporin/itraconazole interaction. Lancet 2:1335-1336.
33. Tucker RM, Denning DW, Hanson LH, Rinaldi MG, Graybill JR, Sharkey PK, Pappagianis D, and Stevens DA (1992) Interaction of azoles with rifampin, phenytoin and carbamazepine: in vitro and clinical observations. Clin Infect Dis 14:165-174.
34. von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, and Shader RI (1998) Inhibition of triazolam hydroxylation by ketoconazole, itraconazole, hydroxyitraconazole and fluconazole in-vitro. Pharm Pharmacol Commun 4:443-445.
35. von Moltke LL, Greenblatt DJ, Schmider J, Duan SX, Wright CE, Harmatz JS, and Shader RI (1996) Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine and by azole antifungal agents. J Clin Pharmacol 36:783-791.
36. Wang JS, Wen X, Backman JT, Taavitsainen P, Neuvonen PJ, and Kivisto KT (1999) Midazolam alpha-hydroxylation by human liver microsomes in vitro: inhibition by calcium channel blockers, itraconazole and ketoconazole. Pharmacol Toxicol 85:157-161.
37. Weerawarna SA, Guha-Biswas M, and Nelson WL (1991) Benzofurans. Improved synthesis of bufuralol, 7-ethyl-2-(2-tert-butylamino-1-hydroxyethyl)benzofuran and 1″-oxobufuralol, 7-acetyl-2-(2-tert-butylamino-1-hydroxyethyl) benzofuran. J Heterocycl Chem 28:1395-1403.
38. Yamano K, Yamamoto K, Katashima M, Kotaki H, Takedomi S, Matsuo H, Ohtani H, Sawada Y, and Iga T (2001) Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution and metabolism data. Drug Metab Dispos 29:443-452.